• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bristol-Myers Squibb

Bristol-Myers Squibb

Bristol-Myers Squibb Company BMY 3 Star

Last Price$50.04Day Change (%)-0.44%
Open Price$50.19Day Change ($)-0.22
Day Range49.75–50.3752-Week Range44.37–57.49

As of Mon 09/15/2014 05:46 PM EST | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. European Commission Approves Bristol-Myers Squibb ’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

    European Commission Approves Bristol-Myers Squibb ’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection

  2. Fed Presidents Lockhart And Fisher Were Active Personal Asset Traders In 2013

    Fed Presidents Lockhart And Fisher Were Active Personal Asset Traders In 2013

  3. Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in ...

    Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)

  4. U.S. Hot Stocks: Hot Stocks to Watch

    U.S. Hot Stocks: Hot Stocks to Watch

  5. BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

    BioPharm America™ 2014 Leads off With Fierce 15 Announcement and Keynote Address Featuring Chief Scientific Officer From Sanofi

  6. Research and Markets: Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014

    Research and Markets: Analyzing the Global Market for Active Pharmaceutical Ingredients - 2014

  7. Finding the True Champion Dividend-Growth Funds

    There is more competition among dividend-growth funds, making it harder to truly stand out.

  8. Gilead Sciences Carving Out a Wider Moat

    StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.